Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (03.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 03.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 07.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Unternehmen & Branche
| Name | Aptevo Therapeutics Inc. |
|---|---|
| Ticker | APVO |
| CIK | 0001671584 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 10,2 Mio. USD |
| Beta | 1,51 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -25,967,000 | -87.27 | 27,194,000 | 17,381,000 | |
| 2025-09-30 | 10-Q | -7,549,000 | -2.23 | 26,996,000 | 17,392,000 | |
| 2025-06-30 | 10-Q | -6,204,000 | -8.40 | 15,624,000 | 6,524,000 | |
| 2025-03-31 | 10-Q | -6,408,000 | -4.39 | 8,342,000 | -1,473,000 | |
| 2024-12-31 | 10-K | -24,130,000 | -###.## | 15,591,000 | 4,755,000 | |
| 2024-09-30 | 10-Q | -5,101,000 | -357.86 | 15,146,000 | 4,420,000 | |
| 2024-06-30 | 10-Q | -5,883,000 | -###.## | 14,921,000 | 4,463,000 | |
| 2024-03-31 | 10-Q | -6,834,000 | -368.21 | 17,629,000 | 6,103,000 | |
| 2023-12-31 | 10-K | -17,411,000 | -###.## | 24,842,000 | 12,221,000 | |
| 2023-09-30 | 10-Q | -6,334,000 | -22.16 | 27,129,000 | 14,718,000 | |
| 2023-06-30 | 10-Q | -7,948,000 | -53.95 | 28,912,000 | 16,253,000 | |
| 2023-03-31 | 10-Q | 2,773,000 | 17.38 | 34,969,000 | 23,256,000 | |
| 2022-12-31 | 10-K | 3,114,000 | 8,027,000 | 1.57 | 34,215,000 | 17,974,000 |
| 2022-09-30 | 10-Q | 3,114,000 | -7,644,000 | -1.50 | 31,695,000 | 15,762,000 |
| 2022-06-30 | 10-Q | 3,114,000 | 28,010,000 | 5.58 | 38,799,000 | 23,047,000 |
| 2022-03-31 | 10-Q | 3,114,000 | -7,697,000 | -1.55 | 45,184,000 | -5,884,000 |
| 2021-12-31 | 10-K | 12,292,000 | -28,457,000 | -6.07 | 56,601,000 | 1,216,000 |
| 2021-09-30 | 10-Q | 3,096,000 | -6,997,000 | -1.43 | 64,005,000 | 7,292,000 |
| 2021-06-30 | 10-Q | 3,110,000 | -7,932,000 | -1.75 | 71,474,000 | 13,881,000 |
| 2021-03-31 | 10-Q | 2,421,000 | -7,256,000 | 68,753,000 | 10,504,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-10 | Grant Grady III | Director | Open Market Purchase | 13,513 | 1.49 | 20,134.37 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.